Known targets — ChEMBL curated mechanism
DRD2DRD3DRD4GNRHRHRH1HTR2AHTR2CSLC6A2SLC6A4SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Pamoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | ME2 | P23368 | 1/20 | 0.56 |
| ▸ | ME1 | P48163 | 1/20 | 0.56 |
| ▸ | ME3 | Q16798 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamoic Acid SCHEMBL248780 | 0.97 | GPR35 (0.71) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL1457853 | 0.97 | GPR35 (0.71) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5420259 | 0.97 | GPR35 (0.71) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL11315960 | 0.97 | GPR35 (0.71) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL587128 | 0.97 | GPR35 (0.71) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL8894325 | 0.95 | GPR35 (0.69) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5014430 | 0.94 | POLB (0.83) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5012893 | 0.91 | POLB (0.83) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL446833 | 0.83 | GPR35 (1.00) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5721 | 0.83 | GPR35 (1.00) | GPR35POLBME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421266-B2 | Safety of pseudoephedrine drug products | PISGAH LABORATORIES, INC. (US) | 2016-08-23 | — | — | US | claimed |
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | PISGAH LABORATORIES, INC. | 2014-06-26 | — | — | US | claimed |
| US-8575151-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | Pisgah National Laboratories, Inc. (US) | 2013-11-05 | — | — | US | claimed |
| US-8367693-B1 | Opioid salts and formulations exhibiting anti-abuse anti-dose dumping properties | PISGAH LABORATORIES, INC. (US) | 2013-02-05 | — | — | US | claimed |
| US-7858663-B1 | Physical and chemical properties of thyroid hormone organic acid addition salts | PISGAH LABORATORIES, INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2009-10-15 | — | — | US | claimed |
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2008-11-27 | — | — | US | claimed |
| CN-115477590-B | Fengomod medicinal salt, preparation method, pharmaceutical composition containing same and application | 上海云晟研新生物科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-115477590-A | Fingolimod medicinal salt, preparation method, pharmaceutical composition containing same and application | 上海博志研新药物技术有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022253077-A1 | PHARMACEUTICAL SALT OF FINGOLIMOD, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | 上海博志研新药物技术有限公司 | 2022-12-08 | — | — | WO | disclosed |
| CN-114249800-A | Preparation method of pamoic acid polypeptide drug | 深圳市星银医药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-110934868-A | Insoluble compound, pharmaceutical composition and application thereof | 合肥合源药业有限公司 | 2020-03-31 | — | — | CN | disclosed |
| EP-2268391-B1 | METHOD FOR ADDITION OF AN ALKALI METAL PROMOTER TO A DEHYDROGENATION CATALYST | FINA TECHNOLOGY (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008138783-A1 | EXPOSURE AGENT FOR DETECTION OF VITAMIN D | NORDIC BOISCIENCE A/S (DK) | 2008-11-20 | — | — | WO | disclosed |
| US-4883786-A | CARDIOTROPIC AGENTS | MAGIS FARMACEUTICI SRL (IT) | 1989-11-28 | — | — | US | disclosed |
| EP-0167115-B1 | NEW DERIVATIVES OF L-CARNITINE | MAGIS FARMACEUTICI S.P.A. (IT) | 1988-04-20 | — | — | EP | disclosed |
| EP-0167115-A2 | New derivatives of L-carnitine | MAGIS FARMACEUTICI S.P.A. (IT) | 1986-01-08 | — | — | EP | disclosed |
| US-4175207-A | TETRAALKALI SALTS OF 3,3',4,4'-BENZOPHENONE TETRACARBOXYLIC ACID | ELLIOTT STANLEY B | 1979-11-20 | — | — | US | disclosed |
| US-4166891-A | BENZOPHENONE TETRACARBOXYLIC ACID SALT COMPLEXED WITH A POLYMER | ELLIOTT STANLEY B | 1979-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | SLC6A2, SLC18A2, SLC6A3 | HTR2A 95/4885GPR35 1149/4885POLB 2400/4885 |
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | SORD, ABCB11, ABCB1 | HTR2A 1115/4885GPR35 827/4885POLB 3068/4885 |
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | SLC18A2, SLC18A1, SLC6A2 | HTR2A 101/4885GPR35 763/4885POLB 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.